BRIEF-Bristol-Myers Squibb says U.S. FDA accepts for priority review the sBLA for Opdivo

* U.S. Food and Drug Administration accepts for priority review the supplemental biologics license application for Opdivo (nivolumab) in previously treated patients with advanced form of bladder cancer